(Q25257862)

English

A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

object named as

Vincent Bours

0 references

author name string

Pierre A Robe

1

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Didier Martin

2

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Adelin Albert

3

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Manuel Deprez

4

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Alain Chariot

5

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

language of work or name

0 references

publication date

31 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

1

0 references

29

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

7 April 2017

Aberrant rel/nfkb genes and activity in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

7 April 2017

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

7 April 2017

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

Moving disease biology from the laboratory to the clinic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

Nuclear factor-kappa B, cancer, and apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

28 September 2017

Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

31 May 2018

Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368982

31 May 2018

Cell cycle regulation of NF-kappa b-binding activity in cells from human glioblastomas.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-29

21 January 2018

Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-29

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-29

21 January 2018

Identifiers

10.1186/1471-2407-6-29

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Dimensions Publication ID

0 references

release_3ndd237gtncxld3wepmuyocphi

1 reference

https://api.fatcat.wiki/v0/release/3ndd237gtncxld3wepmuyocphi

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q25257862&oldid=2177074014"